

# Genotypic Diversity among *Salmonella* Typhi Isolated from Children Living in Informal Settlements in Nairobi, Kenya

Susan Mutile Kawai<sup>1,2,\*</sup>, Julius Oyugi<sup>2,3</sup>, Cecilia Mbae<sup>1</sup>, Celestine Wairimu<sup>1</sup>, Kelvin Kering<sup>1</sup>, Collins Kebenei<sup>1</sup>, Peter Muturi<sup>1</sup>, Sylvia Omulo<sup>3,4,5</sup>, Samuel Kariuki<sup>1,6,7</sup>

<sup>1</sup>Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya

<sup>2</sup>Department of Medical Microbiology and Immunology, University of Nairobi, Kenya

<sup>3</sup>University of Nairobi Institute of Tropical and Infectious Diseases, Nairobi, Kenya

<sup>4</sup>Paul G. Allen School for Global Health, Washington State University, Pullman, USA

<sup>5</sup>Washington State University Global Health–Kenya, Nairobi, Kenya

<sup>6</sup>Wellcome Sanger Institute, Cambridge, United Kingdom

<sup>7</sup>Drugs for Neglected Diseases Initiative, Nairobi, Kenya

## Research Article

## Open Access &

## Peer-Reviewed Article

DOI: 10.14302/issn.2690-4721.ijcm-24-5195

## Corresponding author:

Susan Mutile Kawai, Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.

## Keywords:

*S. Typhi*; Haplotype 58; symptomatic; asymptomatic; antimicrobial resistance; genetic diversity; informal settlements

**Received:** July 10, 2024

**Accepted:** July 31, 2024

**Published:** September 16, 2024

## Citation:

Susan Mutile Kawai, Julius Oyugi, Cecilia Mbae, Celestine Wairimu, Kelvin Kering et al. (2024) Genotypic Diversity among *Salmonella* Typhi Isolated from Children Living in Informal Settlements in Nairobi, Kenya. International Journal of Clinical Microbiology - 1(3):18-27. <https://doi.org/10.14302/issn.2690-4721.ijcm-24-5195>

## Abstract

The persistence of multidrug-resistant (MDR) *Salmonella* Typhi (*S. Typhi*) is a challenge especially in regions where typhoid is endemic. Surveillance of circulating genotypes of MDR *S. Typhi* is crucial in typhoid acute cases and carriers. This study aimed to investigate genotypic diversity of *S. Typhi* from symptomatic and asymptomatic children in endemic settings in Nairobi, Kenya. Symptomatic and asymptomatic individuals'  $\leq 16$  years were recruited at four health facilities and tested for typhoid through stool cultures. The *S. Typhi* isolates were subjected to antibiotic susceptibility testing to investigate multidrug resistance. The MDR *S. Typhi* isolates' DNA was extracted and illumina sequenced. Raw reads were *de novo* assembled and analyzed by pathogen-watch. From the 90 sequenced isolates, 60 (67%) were confirmed to be *S. Typhi* (sequence Type 1 and genotype 4.3.1). Out of the 60 *S. Typhi* strains; 39 (65%) had plasmids, from these 38 (97%) had *IncHII* plasmids alone. Out of the 60, 59 (98%) *S. Typhi* isolates had *bla*<sub>TEM-ID</sub>. Point mutations conferring reduced susceptibility to quinolones were detected in 42 (70%) of *S. Typhi* isolates, from these; 14 (33%) had *gyrA* S83Y, and 28 (67%) *gyrB* S464F genes, respectively. This study reports 4.3.1 (H58) as the most dominant *S. Typhi* genotype responsible for spread of MDR phenotypes carried on *IncHII* plasmids. Presence of MDR *S. Typhi* with resistance genes such as *bla*<sub>TEM-ID</sub> and reduced susceptibility to ciprofloxacin especially among asymptomatic individuals, reiterates the need for use of typhoid conjugate vaccine among vulnerable children as a control and prevention measure against typhoid.

## Introduction

Typhoid fever caused by *S. Typhi* is a significant global health challenge, especially in low- and middle-income countries (LMICs) where it is endemic. According to the World Health Organization (WHO), typhoid fever accounts for 11–20 million cases worldwide each year, resulting in approximately 140,000 deaths<sup>1</sup>. In 2017, sub-Saharan Africa (SSA) reported 1.2 million cases of typhoid fever, leading to around 29,000 deaths<sup>2</sup>. In Kenya, the incidence rate of typhoid fever among children aged  $\leq 8$  years is 520 per 100,000 person-years of observation<sup>3</sup>.

Previous studies have identified MDR *S. Typhi* strains (isolates resistant to ampicillin, chloramphenicol and co-trimoxazole) in Kenya from acute cases<sup>4,5</sup> and their presence in the environment continuously undermines the effectiveness of antibiotic therapy. Another major public health concern is typhoid fevers chronic carriage status which may be attributed to MDR *S. Typhi* in some cases<sup>6</sup>. Recurrent excretion of *S. Typhi* in urine and stool by carriers also contributes to the disease's transmission in the community hence the need for vaccine therapy<sup>7,8,9</sup>. Although mass vaccination has been shown to significantly reduce the disease burden of typhoid fever<sup>10,11</sup>, it has not been widely implemented in many LMICs, including Kenya<sup>12,13</sup>.

Despite the endemic nature of typhoid fever in LMICs like Kenya, these countries often lack access to high-quality diagnostic tools such as whole genome sequencing, which can accurately identify and confirm circulating MDR *S. Typhi* genotypes. Previous studies have demonstrated that the MDR H58 lineage of *S. Typhi* has been responsible for multidrug-resistant typhoid fever over the past three decades in SSA and Southeast Asia<sup>14,15</sup>. Over the last twenty years, the MDR H58 lineage has been documented in various countries in Asia and Africa, accounting for a significant burden of typhoid fever<sup>14,15,16</sup>.

Multidrug resistance in *S. Typhi* is primarily associated with the acquisition of large transmissible plasmids<sup>8,9</sup> some of which can range in size from approximately 100 to 110 MDa and are absent in drug-susceptible strains<sup>14</sup>. A study conducted in Thailand reported that 80% of the isolated MDR *S. Typhi* strains carried a self-transmissible plasmid of over 98 MDa, with the main replicon identified as *incHII*<sup>14</sup>.

*S. Typhi* has been reported to carry antimicrobial resistance genes (AMR), such as *bla*<sub>TEM-1</sub> (ampicillin), *sulI*; *dhfr7* (co-trimoxazole), and *catA1* (chloramphenicol)<sup>5,17</sup>. Resistance to quinolones in *S. Typhi* has been associated with point mutations in the quinolone resistance determining region, specifically in the genes housing the DNA topoisomerase IV enzymes<sup>5,21</sup>.

Previous studies in Africa and Asia have focused on MDR *S. Typhi* associated with symptomatic individuals. Although the typhoid carriage state is also quite prevalent in these typhoid endemic regions, there is limited published data on MDR *S. Typhi* from asymptomatic individuals<sup>6,7</sup>. Our study aimed at analyzing the genotypic diversity; phylogenetic comparison of our isolates and those of other countries in Africa and Asia where typhoid is endemic, AMR genes and plasmids associated with MDR *S. Typhi* isolated from symptomatic and asymptomatic children in informal settlements in Nairobi, Kenya.

## Materials and Methods

### *Study site and participants*

We analyzed archived *S. Typhi* isolated from stool samples of participants enrolled in a case-control

study from November 2013 to November 2018. A detailed description of the study population, including participant recruitment, sample collection and microbiology procedures have previously been documented<sup>18</sup>. Briefly, stool samples were collected from children aged  $\leq 16$  years living in Kibera and Mukuru informal settlements which are 6.6km and 20km from Nairobi city centre respectively.

#### *Inclusion and exclusion criteria*

The symptomatic individuals (cases) were recruited into the study if  $\leq 16$  years and presenting to study health facilities with a history of fever  $\geq 38^{\circ}\text{C}$  for the last three days and/or with three or more diarrhoea episodes. The cases were excluded from the study if they had taken antibiotics in the last 3 days. Asymptomatic (controls) children were recruited into the study if they presented to the clinics for vaccinations and/or with non-typhoid related symptoms.

#### *Isolate revival and antibiotic susceptibility testing*

Archived *S. Typhi* isolates previously confirmed through serology techniques (polyvalent O and monovalent antisera (9, d and vi) (Remel ltd, Europe), and frozen in Tryptone soy broth (Oxoid, Basingstoke, UK) with 15% glycerol (Span scTM Chemie, India) in a  $-80^{\circ}\text{C}$  freezer, at Kenya Medical Research institute (KEMRI) microbiology labs, were revived on Salmonella-Shigella agar, then sub-cultured on Mueller Hinton agar (Both from Oxoid, Basingstoke, UK) to confirm their viability. The Kirby Bauer disc diffusion method was used for antibiotic susceptibility testing (AST). For this, a loop full of the one discrete colony was emulsified in normal saline and the suspension adjusted to 0.5 MacFarland.

A sterile swab was then used to spread the suspension onto Mueller Hinton agar (Oxoid, Basingstoke, UK) prior to dispensing the antibiotic discs. Isolates were tested for susceptibility to amoxicillin-clavulanic acid (AMC, 30  $\mu\text{g}$ ), ampicillin (AMP, 10  $\mu\text{g}$ ), azithromycin (AZM, 15  $\mu\text{g}$ ), cefotaxime (CTX, 30  $\mu\text{g}$ ), cefpodoxime (CPD, 10  $\mu\text{g}$ ), ceftazidime (CAZ, 30  $\mu\text{g}$ ), ceftriaxone (CRO, 30  $\mu\text{g}$ ), chloramphenicol (CHL, 30  $\mu\text{g}$ ), ciprofloxacin (CIP, 5  $\mu\text{g}$ ), gentamicin (GEN, 10  $\mu\text{g}$ ), kanamycin (KAN, 30  $\mu\text{g}$ ), nalidixic acid (NAL, 30  $\mu\text{g}$ ), co-trimoxazole (SXT, 25  $\mu\text{g}$ ), and tetracycline (TET, 30  $\mu\text{g}$ ), all from Oxoid Basingstoke, UK. *Escherichia coli* ATCC 25922 was used as the control organism for the AST. The 2022 Clinical and Laboratory Standards Institute guidelines (CLSI M 100)<sup>19</sup> were applied when interpreting AST results. At minimum, we defined multidrug resistance as combined resistance to ampicillin, chloramphenicol, and co-trimoxazole.

#### *Genotypic characterization*

The Zymo Research Quick-DNA Fungal/Bacterial kit (California, USA) was used for genomic DNA extraction following the instructions provided. A Nanodrop reader (Thermo Fisher, MA, USA) was used to estimate DNA quality and quantity. Sequencing was conducted at SeqCoast Genomics (New Hampshire, USA) using the Illumina (Nextseq2000, USA) sequencing platform.

The quality of the raw reads was assessed using FastQC v0.11.9<sup>20</sup> followed by *de novo* assembly using the Shovill pipeline v1.1.0 <https://github.com/tseemann/shovill>. The genome size and read lengths were estimated from the reads and adapters were trimmed prior to assembly using SPAdes. Minor assembly errors were corrected by mapping reads back to contigs, and contigs were removed if they were too short and or had too low coverage. Final FASTA with parseable annotations were produced and renamed accordingly for ease of reference.

#### *Genome upload and analysis*

Genome assemblies were uploaded to <https://pathogen.watch/> and multi-locus sequence typing (MLST)

done using the <http://mlst.warwick.ac.uk/mlst/dbs/Senterica> database. *S. Typhi* serotypes and genotypes were confirmed using the Salmonella In Silico Typing Resource (SISTR) and <https://github.com/katholt/genotyphi> databases, respectively. Phylogenetic trees to determine genotypic relationships between our isolates and those previously reported in Africa and Asia were generated using Micro-React, an online web-based tool. We referenced PAARSNP AMR -Library 90370 version 0.0.17 and database sourced from <https://cge.cbs.dtu.dk/services/PlasmidFinder/> to identify AMR genes and plasmids, respectively.

### Statistical analysis

Descriptive statistical data analysis in form of counts (n) and proportions (%) was used to present comparisons in genotypes and lineages, plasmids and AMR genes associated with MDR *S. Typhi* between symptomatic and asymptomatic individuals.

### Results

From a total of 215 archived *S. Typhi*, 90 (42%) were MDR, thus selected for sequencing. Of these, 3 isolates failed at library preparations and 27 (30%) were other organisms including *Citrobacter* sp. (n=1), *Enterobacter* sp. (8), *E. coli* (4), and other *Salmonella* sp. (14). The remaining 60 that were confirmed as *S. Typhi* were drawn equally from symptomatic (cases) 30 (50%) and asymptomatic children, 30 (50%) (controls).

#### *MDR S. Typhi genotypes and lineages*

All 60 *S. Typhi* isolates belonged to the 4.3.1 genotype, with lineage 2 sub lineage EA2 predominating 28 (47%); 13 (46%) symptomatic and 15 (54%) asymptomatic children respectively. Lineage 1 sub lineage EA1 18 (30%) was the next common lineage, 6 (33%) symptomatic and 12 (67%) a symptomatic: followed by Lineage 2 sub lineage EA3 14 (23%), 11 (79%) symptomatic and 3 (21%) a symptomatic, respectively. Phylogenetic analysis showed that the genotypes 4.3.1.1 and 4.3.1.2, reported in our study closely clustered with genotypes from India and Zambia (Figure 1).

#### *Plasmid types and their distribution*

Two types of plasmids were identified in 39 (65%) of the isolates; 38 (97%) of isolates had *IncHIIA/IncHIIIB (R27)* alone, while 1 (3%) had [*IncHIIA/IncHIIIB (R27)* and *IncFII(S)*], plasmids respectively. The plasmid group *IncHIIA/IncHIIIB (R27)* alone was present in, 14 (37%) and 24 (63%) of the isolates obtained from symptomatic and asymptomatic children, respectively. The other plasmid groups, *IncHIIA/IncHIIIB (R27)*, *IncFII(S)* were found in a symptomatic child, 1 (3%).

#### *AMR gene distribution*

All except one *S. Typhi* isolate contained AMR genes that confer resistance to six antimicrobial agents. Ampicillin (*bla<sub>TEM-1D</sub>*), chloramphenicol (*catA1*), co-trimoxazole (*dfr; sul1; sul2*) AMR genes were each observed in 59 (98%) of the isolates, out of these 30 (51%) were from asymptomatic individuals while 29 (49%) were from symptomatic individuals, respectively. Point mutations conferring reduced susceptibility to quinolones were detected in 42 (70%) of *S. Typhi* isolates, 14 (33%) *gyrA S83Y*, and 28 (67%) *gyrB S464F*. Only one isolate from an asymptomatic individual showed resistance to azithromycin conferred by the *mefA; msrD* genes (Figure 2).




Figure 1. Phylogenetic tree comparing *S. Typhi* genotypes from our study with those from other countries in Africa and Asia. We selected 208 *S. Typhi* isolates distributed across 11 African and Asian countries. All *S. Typhi* isolates belonging to genotype 4.3.1 appear to originate from the same branch.




Figure 2. Antimicrobial resistance genes from *S. Typhi* isolated from children  $\leq 16$  years of age from Mukuru and Kibera informal settlements, Nairobi, Kenya

## Discussion

Typhoid carriage has significant importance to the disease transmission in LMICs in SSA and Southeast Asia where the disease is endemic<sup>21</sup>. Countries such as Kenya suffer great disease burden both in its acute and carrier states. Shedding of MDR *S. Typhi* from carriers in the environment plays a major role in the persistence of typhoid fever and AMR in communities, often spreading to vulnerable individuals including children<sup>21,22</sup>.

Our WGS data showed that 30% of the presumed *S. Typhi* had been wrongly classified using serological techniques. These findings are similar to a study conducted in Kenya in 2021. This misidentification of *S. Typhi* highlights the need for strengthening more accurate molecular techniques in diagnostics for future studies especially in LMICs<sup>22</sup>.

We observed that the predominant *S. Typhi* genotype was 4.3.1 in both symptomatic and asymptomatic individuals. The three clades observed; 4.3.1.1 EA1, 4.3.1.2 EA2 and 4.3.1.2 EA3 were all of the East Africa descent. Similar genetic clades were also found among *S. Typhi* isolates from Kibera in a prior study conducted in Kenya. The presence of this MDR genotype in both cases and carriers is evidence that even typhoid carriers are exposed to similar *S. Typhi* strains. This is an indication of human-to-human transmission of *S. Typhi* within this population. MDR *S. Typhi* carriage strains are an important source of transmission of AMR genes to the rest of the community including symptomatic children that get typhoid<sup>23,24</sup>.

We observed that H58 was the sole *S. Typhi* haplotype responsible for MDR genotypes in our isolates. A previous study on the phylo-geographical analysis of the major MDR *S. Typhi* H58 clade from Asia and Africa found that H58 isolates accounted for 63% of the isolates from eastern and southern Africa. African countries including; Kenya, Tanzania, Malawi, and South Africa all had H58 lineages I and II reported, confirming that H58 *S. Typhi* was brought to the continent more than once from South Asia<sup>25</sup>. These findings were similar to other studies conducted in Asian countries including India and Pakistan<sup>23,26</sup>. Similar observations were made in a separate study on phylo-geography and incidence of MDR typhoid fever in SSA<sup>26</sup>. These circulating MDR *S. Typhi* genotypes that originated from South East Asia could have spread overtime due to intercontinental travel, leading to multiple introductions of this genotype between the two continents<sup>26</sup>.

Our study reported *S. Typhi* that harboured the *IncHII* plasmids (66.7%) in both asymptomatic (63%) and symptomatic (37%) individuals. Notably the asymptomatic individuals were observed to have more *S. Typhi* that carried these *IncHII* plasmids which have been associated with acquisition of MDR phenotypes<sup>26,27</sup>. More than half of the H58 *S. Typhi* strains distributed well within the asymptomatic and symptomatic participants were determined to harbour the *IncHII* plasmids. Previous studies<sup>21,25</sup> closely linked these plasmids to resistance to first-line antimicrobials in *S. Typhi*. MDR *S. Typhi* isolates from several Asian countries, including Vietnam<sup>28</sup>, India<sup>29</sup>, and Pakistan<sup>30</sup> have been found to possess similar *IncHII* plasmids carry genes for resistance to almost all widely prescribed antibiotics. In a separate study, *IncHII-PST6* plasmids were found in 74% of the H58 isolates that had the MDR element. These isolates were from South Asia, Southeast Asia, and East Africa, suggesting that the *IncHII-PST6* MDR plasmid and H58 *S. Typhi* were transmitted across continents<sup>25</sup>. Presence of these large self-transmissible *IncHII* plasmids in our isolates is an indication of the persistence of circulating MDR *S. Typhi* genotypes. This further suggests that plasmid-mediated horizontal transfer has been the primary mechanism for the transmission of antimicrobial resistance determinants in these typhoid endemic setting in Kenya<sup>31</sup>.



Our data showed presence of AMR genes (*bla<sub>TEM-1D</sub>*/*catA1*/*dfrA7*; *sul1*; *sul2*) coding for resistance to first line drugs (ampicillin, chloramphenicol and co-trimoxazole) in 98% of the *S. Typhi* sequenced. These AMR genes from MDR *S. Typhi* were also reported in another study done in Kenya<sup>22</sup>. A separate study focusing on a global scale reported AMR genes linked to MDR H58 *S. Typhi* strains as *bla<sub>TEM-1</sub>* (ampicillin resistance), *dfrA7*, *sul1* and *sul2* (resistance to trimethoprim and sulfonamides, respectively), and *catA1* (chloramphenicol resistance), and *strAB* (streptomycin resistance). The presence of high multi drug resistance observed in our isolates could be attributed to overtime ineffectiveness of first line drugs due to their initial overuse and misuse through over the counter purchases and empirical treatment for multiple infections in Kenya<sup>17, 22, 32</sup>.

In addition to the resistance to first line drugs, some isolates had AMR genes such as *tetA*; *tetB*, *mefA*; *msrD* for tetracycline and azithromycin drugs. Similar findings have been reported in isolates from SSA countries such as Malawi, Kenya and South Africa<sup>21, 25</sup>. Point mutations (*gyrB S464F* and *gyrA S83Y*) conferring reduced susceptibility to quinolones were also observed. A separate study reported similar findings of having the most frequent QRDR mutations to be changes in codon 83 of *gyrA*. The increase of *gyrA* mutations has subsequently resulted in high rates of MDR H58 strains with reduced susceptibility to fluoroquinolones. This observation likely reflects the therapeutic use of fluoroquinolones such as ciprofloxacin to treat typhoid over time in Africa and Asian countries<sup>25</sup>.

The co-occurrence of these genes in some of the isolates in both symptomatic and asymptomatic individuals is worrisome and could be as a result of misuse of these antibiotics overtime leading to their reduced efficacy. Typhoid disease caused by such *S. Typhi* would be difficult to treat with drugs like ciprofloxacin which is currently used to treat typhoid infections in Kenya. The presence of these genes in asymptomatic individuals is evident that carriers constantly shed *S. Typhi* in the community and contribute to persistence of the disease in the community<sup>30, 32</sup>. Our study has a limitation that asymptomatic individuals were not followed up to ascertain the period they were shedding *S. Typhi* and whether the AMR phenotypes changed over time.

### Conclusion

It is evident that H58 is responsible for MDR Typhoid fever infections since its emergence and persistent spread in SSA, and particularly Kenya. Our study reports presence of MDR H58 in both symptomatic and asymptomatic children. Presence of MDR *S. Typhi* in carriage poses a major challenge in prevention and control of typhoid in endemic settings. Our study therefore recommends introduction of Typhoid Conjugate Vaccine (TCV) for control of both the pathogen and MDR *S. Typhi* phenotypes as effective alternative tool for management of typhoid fever, as effective antimicrobial agents are either unavailable or too expensive to be afforded by patients from these endemic settings.

### List of abbreviations

AMR - Antimicrobial Resistance; AST - Antibiotic Sensitivity Testing; DNA - Deoxyribonucleic Acid; EA - East Africa; H58 - Haplotype 58; KEMRI - Kenya Medical Research Institute; LMIC - Low- and Middle-Income Countries; MA - Massachusetts; MDA - Multiple Displacement Amplification; MDR - Multidrug Resistant; MLST - Multi-locus Sequence Typing; SSA - sub Saharan Africa; SNP - Single Nucleotide Polymorphism; TCV - Typhoid Conjugate Vaccine; UK - United Kingdom; USA - United States of America; WGS - Whole Genome Sequencing; WHO - World Health Organization

### Acknowledgement

This research was financially supported by the National Institute of Health (NIH) National Institute of Allergy and Infectious Diseases (Grant Number: R01 AI099525).

### Ethical considerations

The parents/guardians of all our participants ( $\geq 16$  years) provided a written informed consent to participate in the study. In addition, children aged 13-16 years also gave verbal assent to be recruited into the study. The consenting process was done by trained study staff at the study sites. The mother study which provided archived samples utilized in this study obtained ethical approval from the Kenya Medical Research Institute's Scientific and Ethics Review Unit (SSC Protocol No. 2076). Additional ethical approval to conduct this study was obtained from the University of Nairobi and Kenyatta National Hospital ethical review committee study no. P950/12/2021. The National Commission for Science and Technology and Innovation in Kenya provided this study with a research license no. NACOSTI/P/22/20305. To ensure participant confidentiality and anonymity, unique research identification numbers were used to de-identify the archived samples. The Declaration of Helsinki basic principles on human research ethics were upheld during the conducting of this study.

### Supplementary data

The data analysed and used for this study are available from the corresponding author on request. The *S. Typhi* genome FASTA files were deposited on NCBI gene bank [https://submit.ncbi.nlm.nih.gov/wgs\\_common/report/SUB14353648](https://submit.ncbi.nlm.nih.gov/wgs_common/report/SUB14353648).

Supplementary data

### References

1. World Health Organization. Typhoid; 2018. Available from: <https://www.who.int/news-room/fact-sheets/detail/typhoid>. Accessed May 6, 2021.
2. Kim JH, Choi J, Kim C, Pak GD, Parajulee P, Haselbeck A, et al. Mapping the incidence rate of typhoid fever in sub-Saharan Africa. *PLoS Negl Trop Dis*. 2024 Feb 26;18(2): e0011902. doi: 10.1371/journal.pntd.0011902. Epub ahead of print. PMID: 38408128.
3. Breiman RF, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng JB, et al. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: Implications for typhoid vaccine use in Africa. *PLoS One* 2012;7. doi: 10.1371/journal.pone.0029119
4. Mengo, D., Kariuki, S., and Muigai, A. . *Salmonella* enteric serovar Typhi in Nairobi, Kenya from 2004 to 2006. *The Journal Of Infection In Developing Countries*, 2010; 6: 393–396.
5. Kawai, S. , Kangogo, M. , Muigai, A. and Kariuki, S. (2018) Analysis of Trends in Resistance to Fluoroquinolones and Extended Spectrum Beta-Lactams among *Salmonella* Typhi Isolates Obtained from Patients at Four Outpatient Clinics in Nairobi County, Kenya. *Advances in Microbiology*, 8, 578-588. doi: 10.4236/aim.2018.87038.
6. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. *Salmonella* chronic carriage: epidemiology, diagnosis, and gallbladder persistence. *Trends Microbiol*. 2014 Nov;22(11):648-55. doi: 10.1016/j.tim.2014.06.007. Epub 2014 Jul 22. PMID: 25065707; PMCID: PMC4252485.



7. Mirza S., Kariuki S., Mamun K. Z., Beeching N. J., and H. C. A. Analysis of plasmid and chromosomal DNA of multidrug-resistant *Salmonella enterica* serovar Typhi from Asia. *Journal of Clinical Microbiology*, 2000; 38, 1449–1452.
8. Bentsi-Enchill AD, Hombach J. Revised global typhoid vaccination policy. *Clin Infect Dis*. 2019;68(Suppl 1):S31. doi:10.1093/CID/CIY927
9. World Health Organization. Typhoid vaccines: WHO position paper, March 2018-recommendations. *Vaccine*. 2019;37(2):214–216. doi:10.1016/J.VACCINE.2018.04.022
10. Ouedraogo A, Diarra A, Nébié I, Barry N, Kabore JM, et al. Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. *J Pediatric Infect Dis Soc*. 2023 Sep 27;12(9):513-518. doi: 10.1093/jpids/piad058. PMID: 37589596; PMCID:
11. Olaru ID, Chingono RMS, Bottomley C, Kandiye FR, et al. The effect of a comprehensive typhoid conjugate vaccine campaign on antimicrobial prescribing in children in Harare, Zimbabwe: a mixed methods study. *Lancet Glob Health*. 2023 Sep;11(9):e1422-e1431. doi: 10.1016/S2214-109X(23)00319-4. PMID: 37591588. PMCID: PMC10533206.
12. Nampota-Nkomba N, Nyirenda OM, Khonde L, Mapemba V, et al. Typhoid Vaccine Acceleration Consortium team. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. *Lancet Glob Health*. 2022 Sep;10(9):e1326-e1335. doi: 10.1016/S2214-109X(22)00275-3. PMID: 35961356; PMCID: PMC9380257.
13. Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, et al. TyVAC Malawi Team. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. *N Engl J Med*. 2021 Sep 16;385(12):1104-1115. doi: 10.1056/NEJMoa2035916. PMID: 34525285; PMCID: PMC82027
14. Dyson, Zoe A, Duy Pham Thanh, Ladaporn Bodhidatta, Carl Jeffries Mason, et al. (2017). Whole Genome Sequence Analysis of *Salmonella* Typhi Isolated in Thailand before and after the Introduction of a National Immunization Program. *PLoS Negl Trop Dis.*, 11(1), e0005274.
15. Danielle J. Ingle, Satheesh Nair, Hassan Hartman, Philip M. Ashton, et al. (2019). Informal genomic surveillance of regional distribution of *Salmonella* Typhi genotypes and antimicrobial resistance via returning travellers. *PLoS Neglected Tropical Diseases*, 0007620.
16. Huimin Qian, Siyun Cheng, Guoye Liu, Zhongming Tan, Chen Dong, et al. (2020). Discovery of seven novel mutations of *gyrB*, *parC* and *parE* in *Salmonella* Typhi and Paratyphi strains from Jiangsu Province of China. *Sci Rep*, 10: 7359.
17. Ng'eno E, Lind M, Audi A, et al. Dynamic Incidence of Typhoid Fever over a 10-Year Period (2010–2019) in Kibera, an Urban Informal Settlement in Nairobi, Kenya. *The American Journal of Tropical Medicine and Hygiene*. 2023;109(1):22-31. doi:10.4269/ajtmh.22-0736
18. Mbae, C., Mwangi, M., Gitau, N. et al. Factors associated with occurrence of salmonellosis among children living in Mukuru slum, an urban informal settlement in Kenya. *BMC Infect Dis* 20, 422 (2020). <https://doi.org/10.1186/s12879-020-05134-z>
19. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.
20. Andrews, Simon. "FastQC: a quality control tool for high throughput sequence data." (2010).

21. Samuel Kariuki, Zoe A Dyson, Cecilia Mbae, Ronald Ngetich, Susan M Kawai, et al. Multiple introductions of multidrug-resistant typhoid associated with acute infection and asymptomatic carriage, Kenya *eLife* 2021; 10: e67852
22. Kariuki, S., Revathi, G., Kiiru, J., Mengo, D. M., Mwituria, J., et al. Typhoid in Kenya is associated with a dominant multidrug-resistant *Salmonella enterica* serovar Typhi haplotype that is also widespread in Southeast Asia. *Journal of Clinical Microbiology*, 2010; 48: 2171–2176.
23. Phan, M. D., C. Kidgell, S. Nair, K. E. Holt, A. K. et al. (2009). Variation in *Salmonella enterica* serovar Typhi IncHII plasmids during the global spread of resistant typhoid fever. *Antimicrobial Agents Chemotherapy*, 53, 716–727
24. Ochieng C, Chen JC, Osita MP, Katz LS, Griswold T, et al. Molecular characterization of circulating *Salmonella* Typhi strains in an urban informal settlement in Kenya. *PLoS Negl Trop Dis*. 2022 Aug 25;16(8):e0010704. doi: 10.1371/journal.pntd.0010704. PMID: 36007074; PMCID: PMC9451065.
25. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, Kingsley RA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella* Typhi identifies inter- and intracontinental transmission events. *Nat Genet*. 2015 Jun;47(6):632-9. doi: 10.1038/ng.3281. Epub 2015 May 11. PMID: 25961941; PMCID: PMC4921243.
26. Baker, S., K. Holt, E. van de Vosse, P. Roumagnac, S. Whitehead, E. et al. 2008. High-throughput genotyping of *Salmonella enterica* serovar Typhi allowing geographical assignment of haplotypes and pathotypes within an urban District of Jakarta, Indonesia. *J. Clin. Microbiol*. 46:1741-1746
27. Park, S.E., Pham, D.T., Boinett, C. et al. The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. *Nat Commun* 9, 5094 (2018). <https://doi.org/10.1038/s41467-018-07370-z>
28. Connerton, P., J. Wain, T. Hien, T. Ali, C. Parry, et al. 2000. Epidemic typhoid in Vietnam: molecular typing of multiple-antibiotic-resistant *Salmonella enterica* serotype Typhi from four outbreaks. *J. Clin. Microbiol*. 38:895-897
29. Joshi, S., and S. K. Amarnath. 2007. Fluoroquinolone resistance in *Salmonella typhi* and *S. paratyphi A* in Bangalore, India. *Trans. R. Soc. Trop. Med. Hyg*. 101:308-310.
30. Phan, M. D., C. Kidgell, S. Nair, K. E. Holt, A. K. Turner, et al. 2009. Variation in *Salmonella enterica* serovar Typhi IncHII plasmids during the global spread of resistant typhoid fever. *Antimicrob. Agents Chemother*. 53:716-727.
31. Onken A, Moyo S, Miraji MK, Bohlin J, Marijani M, et al. (2024) Predominance of multidrug-resistant *Salmonella* Typhi genotype 4.3.1 with low-level ciprofloxacin resistance in Zanzibar. *PLOS Neglected Tropical Diseases* 18(4): e0012132. <https://doi.org/10.1371/journal.pntd.0012132>
32. Kasiano P, Kawai S, Kiiru S, Nyerere A, Kariuki S. Typhoidal salmonella disease in Mukuru informal settlement, Nairobi Kenya; carriage, diversity, and antimicrobial resistant genes. *PLoS One*. 2024 Feb 23;19(2):e0298635. doi: 10.1371/journal.pone.0298635. PMID: 38394140; PMCID: PC10889635.